Amarin Enters Licensing Agreement with Recordati

Amarin ( (AMRN) ) just unveiled an announcement.

On June 20, 2025, Amarin Corporation entered into a long-term license and supply agreement with Recordati to commercialize VAZKEPA® in 59 European countries. The agreement includes an upfront payment of $25 million, potential milestone payments up to $150 million, and royalties based on net sales. This partnership allows Amarin to streamline its global operations, resulting in approximately $70 million in annual cost savings and an accelerated path to positive cash flow. Additionally, Amarin announced a global restructuring to reduce operating costs, primarily from its European operations, with expected completion by June 30, 2026.

The most recent analyst rating on (AMRN) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Amarin stock, see the AMRN Stock Forecast page.

Spark’s Take on AMRN Stock

According to Spark, TipRanks’ AI Analyst, AMRN is a Neutral.

Amarin’s stock score reflects a challenging financial performance with declining revenues and profitability issues. Despite strong technical indicators, the stock is weighed down by valuation concerns and mixed corporate developments. Strategic global expansion is promising, but U.S. market challenges and shareholder setbacks necessitate caution.

To see Spark’s full report on AMRN stock, click here.

More about Amarin

Amarin is an innovative pharmaceutical company focused on cardiovascular disease management. It aims to enhance scientific understanding and treatment of cardiovascular risks beyond traditional therapies. The company operates in the United States, Europe, and other regions, with commercial partners and suppliers worldwide.

Average Trading Volume: 97,490

Technical Sentiment Signal: Hold

Current Market Cap: $259.8M

For a thorough assessment of AMRN stock, go to TipRanks’ Stock Analysis page.